1460884590-199196ae-2ca8-4a28-bf5b-d257b4b2983b

1. A method of identifying a candidate compound that stimulates hypothalamic proopiomelanocortin (POMC)-derived biologically active peptide secretion, said method comprising:
(a) contacting the candidate compound with a recombinant host cell or a membrane thereof that comprises a G protein-coupled receptor (GPCR), wherein said receptor comprises an amino acid sequence selected from the group consisting of:
(i) the amino acid sequence of SEQ ID NO:2;
(ii) the amino acid sequence of a GPCR encoded by a polynucleotide that is amplifiable by polymerase chain reaction (PCR) on a human genomic DNA sample using primers having the nucleotide sequence set forth in SEQ ID NO: 7 and SEQ ID NO: 8;
(iii) the amino acid sequence of SEQ ID NO: 4;
(iv) the amino acid sequence of SEQ ID NO: 6;
(v) the amino acid sequence of a GPCR encoded by a polynucleotide hybridizing under stringent conditions to the full-length complement of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5;
(vi) the amino acid sequence of a GPCR that has an amino acid sequence having at least 70% identity to SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6; and
(vii) the amino acid sequence of SEQ ID NO:2, but wherein the alanine at amino acid position 398 of SEQ ID NO:2 is substituted with an amino acid selected from the group consisting of lysine, arginine, and histidine,
wherein the receptor couples to a G protein or, wherein the GPCR induces cAMP accumulation; and

(b) determining the ability of the candidate compound to stimulate functionality of the GPCR;
(c) administering a vertebrate with a candidate compound that stimulates functionality of the GPCR; and
(d) measuring an energy homeostasis-related parameter of the vertebrate, wherein the energy homeostasis-related parameter is selected from the group consisting of body mass, adiposity, and percentage body fat due to food intake,
wherein the ability of the candidate compound to decrease an energy homeostasis-related parameter of the vertebrate is indicative of the candidate compound being a compound that stimulates hypothalamic POMC-derived biologically active peptide secretion.
2. The method of claim 1, wherein the GPCR comprises the amino acid sequence of SEQ ID NO: 2.
3. The method of claim 1, wherein the GPCR comprises the amino acid sequence of a GPCR that has an amino acid sequence having at least 70% identity to SEQ ID NO: 2.
4. The method of claim 3, wherein the GPCR comprises an amino acid sequence having at least 85% identity to SEQ ID NO: 2.
5. The method of claim 1, wherein the POMC-derived biologically active peptide is selected from the group consisting of adrenocorticotropic hormone (ACTH), \u03b2-endorphin, alpha-melanocyte stimulating hormone (\u03b1-MSH), beta-melanocyte stimulating hormone (\u03b2-MSH) and gamma-melanocyte stimulating hormone (\u03b3-MSH).
6. The method of claim 1, wherein said determining is through the measurement of the level of a second messenger.
7. The method of claim 6, wherein the second messenger is cAMP.
8. The method of claim 1, wherein said determining is by using a Melanophore assay or by measuring GTP\u03b3S binding to a membrane comprising the GPCR or by using a cAMP-responsive reporter assay.
9. The method of claim 1, wherein the vertebrate is a non-human mammal.
10. The method of claim 1, wherein the vertebrate is a human.
11. The method of claim 1, wherein the method comprises identifying an agonist of the GPCR.
12. The method of claim 11, wherein the agonist is an agonist of human GPR101.
13. The method of claim 1, wherein the method comprises identifying a partial agonist of the GPCR.
14. The method of claim 13, wherein the partial agonist is a partial agonist of human GPR101.
15. A method of screening candidate compounds as pharmaceutical agents for a POMC-derived biologically active peptide-related disorder, said method comprising:
(a) contacting the candidate compound with a recombinant host cell or a membrane thereof that comprises a G protein-coupled receptor (GPCR), wherein said receptor comprises an amino acid sequence selected from the group consisting of:
the amino acid sequence of SEQ ID NO:2;
the amino acid sequence of a GPCR encoded by a polynucleotide that is amplifiable by polymerase chain reaction (PCR) on a human genomic DNA sample using primers having the nucleotide sequence set forth in SEQ ID NO: 7 and SEQ ID NO: 8;
(iii) the amino acid sequence of SEQ ID NO: 4;
(iv) the amino acid sequence of SEQ ID NO: 6;
(v) the amino acid sequence of a GPCR encoded by a polynucleotide hybridizing under stringent conditions to the full-length complement of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5;
(vi) the amino acid sequence of a GPCR that has an amino acid sequence having at least 70% identity to SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6; and
(vii) the amino acid sequence of SEQ ID NO:2, but wherein the alanine at amino acid position 398 of SEQ ID NO:2 is substituted with an amino acid selected from the group consisting of lysine, arginine, and histidine,
wherein the receptor couples to a G protein or, wherein the GPCR induces cAMP accumulation; and

(b) detecting a ligand bound to said GPCR,
(c) administering a vertebrate with a ligand that binds to said GPCR; and
(d) measuring an energy homeostasis-related parameter of the vertebrate, wherein the energy homeostasis-related parameter is selected from the group consisting of body mass, adiposity, and percentage body fat due to food intake,
wherein the ability of the ligand to decrease an energy homeostasis-related parameter of the vertebrate is indicative of the ligand being suitable as a pharmaceutical agent for a POMC-derived biologically active peptide-related disorder.
16. The method of claim 15, wherein the GPCR comprises the amino acid sequence of SEQ ID NO: 2.
17. The method of claim 15, wherein the POMC-derived biologically active peptide is selected from the group consisting of adrenocorticotropic hormone (ACTH), \u03b2-endorphin, alpha-melanocyte stimulating hormone (\u03b1-MSH), beta-melanocyte stimulating hormone (\u03b2-MSH) and gamma-melanocyte stimulating hormone (\u03b3-MSH).
18. The method of claim 15, wherein the GPCR comprises an amino acid sequence having at least 70% identity to SEQ ID NO: 2.
19. The method of claim 18, wherein the GPCR comprises an amino acid sequence having at least 85% identity to SEQ ID NO: 2.
20. The method of claim 15, wherein the ligand that decreases an energy homeostasis-related parameter of the vertebrate is a ligand of human GPR101.
21. The method of claim 20, wherein the ligand of human GPR101 is a selective ligand.
22. The method of claim 15, wherein the vertebrate is a non-human mammal.
23. The method of claim 15, wherein the vertebrate is a human.
24. A method of identifying a compound that stimulates hypothalamic POMC-derived biologically active peptide secretion, said method comprising:
(a) measuring an energy homeostasis-related parameter of a vertebrate, the vertebrate having been administered a GPR101 ligand, wherein the energy homeostasis-related parameter is selected from the group consisting of body mass, adiposity, and percentage body fat due to food intake;
wherein the ability of the GPR101 ligand to decrease an energy homeostasis-related parameter of the vertebrate is indicative of a compound that stimulates hypothalamic POMC-derived biologically active peptide secretion.
25. The method of claim 24, wherein the vertebrate is a non-human mammal.
26. The method of claim 24, wherein the vertebrate is a human.
27. The method of claim 24, wherein the POMC-derived biologically active peptide is selected from the group consisting of adrenocorticotropic hormone (ACTH), \u03b2-endorphin, alpha-melanocyte stimulating hormone (\u03b1-MSH), beta-melanocyte stimulating hormone (\u03b2-MSH) and gamma-melanocyte stimulating hormone (\u03b3-MSH).
28. The method of claim 24, wherein the GPR101 ligand that decreases an energy homeostasis-related parameter of the vertebrate is further identified as a ligand of human GPR101.
29. The method of claim 24, wherein the GPR101 ligand that decreases an energy homeostasis-related parameter of the vertebrate is an antibody.
30. The method of claim 24, wherein the GPR101 ligand that decreases an energy homeostasis-related parameter of the vertebrate is a selective GPR101 ligand having a selectivity for GPR101 over GPR161.
31. The method of claim 24, wherein the method identifies said GPR101 ligand as a GPR101 agonist.
32. The method of claim 31, wherein the agonist has an EC50 of less than 10 \u03bcM.
33. The method of claim 31, wherein the agonist has an EC50 of less than 1 \u03bcM.
34. The method of claim 31, wherein the agonist has an EC50 of less than 100 nM.
35. The method of claim 31, wherein the agonist has a selectivity for GPR101 over GPR161 of at least 10-fold.
36. The method of claim 31, wherein the agonist is a GPR101 partial agonist.
37. The method of claim 31, wherein the agonist is an agonist of human GPR101.
38. A method of identifying a compound that stimulates hypothalamic proopiomelanocortin (POMC)-derived biologically active peptide secretion, said method comprising:
(a) administering a vertebrate a GPR101 ligand; and
(b) measuring an energy homeostasis-related parameter of the vertebrate, wherein the energy homeostasis-related parameter is selected from the group consisting of body mass, adiposity, and percentage body fat due to food intake,
wherein the ability of the GPR101 ligand to decrease an energy homeostasis-related parameter of the vertebrate is indicative of the GPR101 ligand being a compound that stimulates hypothalamic POMC-derived biologically active peptide secretion.
39. The method of claim 38, wherein the vertebrate is a non-human mammal.
40. The method of claim 38, wherein the vertebrate is a human.
41. The method of claim 38, wherein the POMC-derived biologically active peptide is selected from the group consisting of adrenocorticotropic hormone (ACTH), \u03b2-endorphin, alpha-melanocyte stimulating hormone (\u03b1-MSH), beta-melanocyte stimulating hormone (\u03b2-MSH) and gamma-melanocyte stimulating hormone (\u03b3-MSH).
42. The method of claim 38, wherein the GPR101 ligand is further identified as a ligand of human GPR101.
43. The method of claim 38, wherein the GPR101 ligand is an antibody.
44. The method of claim 38, wherein the GPR101 ligand is a selective GPR101 ligand, said selective. GPR101 ligand having a selectivity for GPR101 over GPR161.
45. The method of claim 38, wherein the method identifies said GPR101 ligand as a GPR101 agonist.
46. The method of claim 45, wherein the agonist has an EC50 of less than 10 \u03bcM.
47. The method of claim 45, wherein the agonist has an EC50 of less than 1 \u03bcM.
48. The method of claim 45, wherein the agonist has an EC50 of less than 100 nM.
49. The method of claim 45, wherein the GPR101 agonist has a selectivity for GPR101 over GPR161 of at least 10-fold.
50. The method of claim 45, wherein the agonist is an agonist of human GPR101.
51. The method of claim 45, wherein the agonist is a GPR101 partial agonist.
52. A method of identifying a compound that stimulates hypothalamic POMC-derived biologically active peptide secretion, said method comprising:
(a) measuring a modulation of energy homeostasis in a vertebrate, the vertebrate having been administered a GPR101 ligand, wherein the modulation is selected from the group consisting of modulation of obesity, modulation of satiety, and modulation of hyperphagia,
wherein the ability of the GPR101 ligand to oppose obesity, to promote satiety, or to oppose hyperphagia in the vertebrate is indicative of the GPR101 ligand being a compound that stimulates hypothalamic POMC-derived biologically active peptide secretion.
53. The method of claim 52, wherein the vertebrate is a non-human mammal.
54. The method of claim 52, wherein the vertebrate is a human.
55. A method of identifying a compound that stimulates hypothalamic proopiomelanocortin (POMC)-derived biologically active peptide secretion, said method comprising:
(a) administering a vertebrate a GPR101 ligand; and
(b) measuring a modulation of energy homeostasis in the vertebrate, wherein the modulation is selected from the group consisting of modulation of obesity, modulation of satiety, and modulation of hyperphagia,
wherein the ability of the GPR101 ligand to oppose obesity, to promote satiety, or to oppose hyperphagia in the vertebrate is indicative of the GPR101 ligand being a compound that stimulates hypothalamic POMC-derived biologically active peptide secretion.
56. The method of claim 55, wherein the vertebrate is a non-human mammal.
57. The method of claim 55, wherein the vertebrate is a human.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A remote signaling receiver system comprising:
a first transmitter device that generates at least a first wireless communication signal;
a second transmitter device that generates at least a second wireless communication signal; and
a receiver that receives the first and second signals, the receiver including a first ASK demodulator for processing the first signal and a second demodulator for processing the second signal, the second demodulator is not affected by amplitude modulation on the second signal, the receiver is programmed to process all received signals using the first ASK demodulator and only when a received signal is not discernible from an output of the first ASK demodulator to process the received signal using the second demodulator.
2. The system of claim 1, wherein the second device and the receiver are supporter on a vehicle and the second signal provides information regarding a condition of a selected vehicle component.
3. The system of claim 2, wherein the second device includes a tire condition sensor and the second signal provides information regarding at least one condition of at least one of the vehicle tires selected from the group of tire pressure, tire temperature, tire thickness and acceleration.
4. The system of claim 1, wherein the first transmitter device signal has a first baud rate and the second transmitter device signal has a second baud rate that is at least two times higher than the first baud rate.
5. The system of claim 1, wherein the second demodulator is one of a FSK demodulator or a PSK demodulator.
6. A vehicle remote keyless entry system comprising:
a portable transmitter that generates a wireless communication signal;
at least one sensor device supported relative to a component on the vehicle that senses a condition of the component and generates a wireless communication signal; and
a receiver supported on the vehicle that receives the wireless communication signal from the transmitter and the sensor signal, the receiver including a first ASK demodulator for processing the wireless communication signal from the transmitter and a second demodulator for processing the sensor signal, the second demodulator is a demodulator that is not sensitive to amplitude modulation, the receiver processing all received signals using the first ASK demodulator and processing a received signal using the second demodulator only if the received signal is not discernable from the processing by the first ASK demodulator.
7. The system of claim 6, wherein the sensor device includes a tire condition sensor and the sensor signal provides information regarding a condition of at least one vehicle tire.
8. The system of claim 6, wherein the second demodulator is a FSK demodulator.
9. The system of claim 6, wherein the transmitter signal has a first baud rate and the sensor signal has a second baud rate that is at least two times higher than the first baud rate.
10. The system of claim 6, wherein the receiver includes a microprocessor that is programmed to receive the transmitter signal on a first channel and the sensor signal on an image channel.
11. The system of claim 6, wherein the second demodulator is a PSK demodulator.
12. A remote signaling receiver system comprising:
an FSK demodulator for receiving a wireless communication signal;
a second, different demodulator for receiving a wireless communication signal; and
a controller that causes a received signal to be processed by the FSK demodulator, the controller determining if an output from the FSK demodulator is squelched during one state and includes noise during an other state, the controller responsively causing the received signal to be processed by the second, different demodulator when the output of the FSK demodulator is squelched during the one state and there is noise during the other state.